Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Activin A is an essential cofactor for osteoclast induction.

K Fuller1, K E Bayley, T J Chambers

  • 1Department of Histopathology, St. George's Hospital Medical School, London, SW17 ORE, United Kingdom. k.fuller@sghms.ac.uk

Biochemical and Biophysical Research Communications
|February 1, 2000
PubMed
Summary

Activin A synergizes with RANKL to promote osteoclast formation. Blocking activin A signaling inhibits osteoclast-like cell development, highlighting its essential role in bone remodeling.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Translating Dental, Oral, and Craniofacial Regenerative Medicine Innovations to the Clinic through Interdisciplinary Commercial Translation Architecture.

Journal of dental research·2021
Same author

Influence of Nonsulfated Polysaccharides on the Properties of Electrospun Poly(lactic-<i>co</i>-glycolic acid) Fibers.

ACS biomaterials science & engineering·2021
Same author

Children's everyday exposure to food marketing: an objective analysis using wearable cameras.

The international journal of behavioral nutrition and physical activity·2017
Same author

Syndrome of Inappropriate Anti-Diuretic Hormone Secretion Secondary to Strongyloides stercoralis Infection in an Allogeneic Stem Cell Transplant Patient: A Case Report and Literature Review.

Transplantation proceedings·2017
Same author

Improving postural control through integration of sensory inputs and visual biofeedback.

Topics in stroke rehabilitation·2016
Same author

TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy.

Leukemia·2016

Area of Science:

  • Bone Biology
  • Cellular Signaling
  • Osteoclastogenesis

Background:

  • Receptor activator of NF-kappaB ligand (RANKL) is crucial for osteoclast formation.
  • Activin A is a cytokine found in bone matrix, secreted by osteoblasts and osteoclasts.

Purpose of the Study:

  • To investigate the role of activin A in osteoclast formation.
  • To determine if activin A synergizes with RANKL in osteoclast differentiation.

Main Methods:

  • Bone marrow precursors were cultured with RANKL and activin A.
  • Soluble activin A type II A receptors (ActR-II(A)) were used to block activin A signaling.
  • Precursors were incubated on bone matrix and with M-CSF to assess sensitivity.

Main Results:

Related Experiment Videos

  • Activin A powerfully synergized with RANKL to induce osteoclast-like cells (OCL) from stromal-depleted bone marrow precursors.
  • Blocking activin A with soluble ActR-II(A) nearly abolished OCL formation, indicating activin A's essentiality.
  • Simultaneous exposure to RANKL and activin A was most effective, reducing resistance seen with M-CSF pre-incubation.
  • Bone matrix enhanced precursor sensitivity to RANKL-induced OCL formation, an effect blocked by soluble ActR-II(A).

Conclusions:

  • Activin A is essential for osteoclast formation and synergizes with RANKL.
  • Activin A, whether from bone matrix or cell release, enhances osteoclastogenic potential.
  • These findings reveal a critical role for activin A in regulating osteoclastic differentiation.